Amphinex
Jump to navigation
Jump to search
Amphinex is a photosensitising agent used in photodynamic therapy for treating superficial cancers.
It has had promising preliminary results in early trials on patients with advanced head and neck cancer[1] [2] [3]
References
- ^ "Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells. | PCI Biotech". Archived from the original on 2011-07-24. Retrieved 2010-04-06. Successful completion of the third dose group in the Amphinex study. March 2010
- ^ http://www.medicalnewstoday.com/articles/176431.php PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial. Jan 2010
- ^ "Inoperable cancers killed by new laser surgery" The Times. UK. 3-April-2010 p15
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |